Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

AstraZeneca offers $443m to buy Omthera

Adds to list of deals to boost flagging pipeline

- PMLiVE

Redx Pharma to open research centre at AstraZeneca’s Alderley Park site

Will focus on hard-to-treat infections

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links